Hyperviscosity in polycythemia vera and other red cell abnormalities

Area of Science:

• Hematology
• Vascular Medicine
• Clinical Pathology

Background:

• Thrombosis is a significant cause of death and disability in polycythemia vera (PV).
• Multiple factors contribute to thrombogenesis in PV, including elevated hematocrit, thrombocytosis, and impaired fibrinolysis.
• Increased whole-blood viscosity and impaired blood flow are primary drivers of thrombotic events in PV.

Purpose of the Study:

• To review the role of hyperviscosity in the pathogenesis of thrombosis in polycythemia vera.
• To highlight the relationship between high hematocrit, impaired blood flow, and thrombotic complications in PV.
• To emphasize the importance of hematocrit reduction in managing PV patients.

Main Methods:

• Review of existing literature on polycythemia vera and thrombosis.
• Analysis of factors contributing to hyperviscosity and impaired blood flow in PV.
• Discussion of hemodynamic principles in PV management.

Main Results:

• Elevated hematocrit in PV leads to abnormal red blood cell aggregation and increased blood viscosity.
• Impaired capillary blood flow due to hyperviscosity causes neurological symptoms and bleeding risks.
• Thrombotic events, including stroke, myocardial infarction, deep vein thrombosis, and pulmonary embolism, are common in PV.

Conclusions:

• Hyperviscosity is a major contributor to thrombotic complications in polycythemia vera.
• Management of PV should prioritize reducing hematocrit to improve blood flow and mitigate thrombosis risk.
• Understanding hemodynamic principles is crucial for effective PV treatment and patient outcomes.